BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Avid Bioservices, Inc. to Present at IBC's Antibody Development and Production Conference


2/24/2012 8:50:57 AM

TUSTIN, CA and SAN DIEGO, CA--(Marketwire - February 23, 2012) - Avid Bioservices, Inc., a leading provider of integrated biomanufacturing services and a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that it will present two posters at IBC's 28th International Antibody Development & Production Conference to be held in San Diego, California, February 29 - March 2, 2012. Avid will highlight its expertise in optimizing purification, scale-up and manufacturing process practice experience with the operation of its cGMP manufacturing facility in Orange County, California, designed to support Avid's contract clients and Peregrine's lead monoclonal antibody, bavituximab.

The following posters from Avid Bioservices will be on display in the exhibit hall February 29 - March 2, 2012 at the Hilton San Diego Bayfront Hotel:

"Rapid development of an animal component-free (ACF) process for clinical production of a monoclonal antibody in NS0 cells with a 44-fold increase in titer as a result of process and scale up optimization"

"Low molecular weight aggregation removal by HIC chromatography -- from benchtop to manufacturing"

In addition, Avid Bioservices will have representatives at Booth #205 in the main hall.

"These presentations are truly representative of our team's expertise in driving the success of our client's projects and overcoming challenges with innovative solutions," said Steven W. King, president of Avid Bioservices. "In both scenarios, we were able to make significant improvements throughout the process that resulted in higher antibody yield, improved cell growth and a more effective purification process to help take our clients project to the next level."

For additional information on IBC's Antibody Development and Production Conference, please visit http://www.ibclifesciences.com/antibodyprod/overview.xml.

About Avid Bioservices
Avid Bioservices provides a comprehensive range of high quality cGMP manufacturing services for the biotechnology and biopharmaceutical industries to support manufacturing of cGMP commercial and clinical products. With over 10 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cell banking, stability testing, clinical and commercial product manufacturing and purification, bulk packaging, final product filling and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.


Contact:
Chris Keenan or Kelly Lord
Peregrine Pharmaceuticals
(800) 987-8256
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES